Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Phase 1b Safety, Dose-finding, Brain Tumor Delivery, and Pharmacokinetics Study of Intranasal NEO100 in Patients With Pediatric-type Select Brain Tumors

NCT06357377 is registered in ClinicalTrials.gov with Neonc Technologies, Inc. as lead sponsor.

NCT NCT06357377
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06357377 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Phase 1b Safety, Dose-finding, Brain Tumor Delivery, and Pharmacokinetics Study of Intranasal NEO100 in Patients With Pediatric-type Select Brain Tumors
Lead sponsor
Neonc Technologies, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
September 8, 2026
Completion date
July 31, 2027
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

choroid plexus carcinoma, childhood, diffuse midline glioma, h3 k27m-mutant, high grade glioma, pediatric tumor of brain, pediatric tumor of brain stem, pediatric tumor of cns, pineocytoma, spinal cord tumor